Zylo Therapeutics Inc.
Greenville, SC · Founded 2017 · CIK 0001721431 · Biotech · Private
Z-pods: a patented sustained-release topical drug delivery platform using proprietary formulation technology
zylotherapeutics.com →- Grants
- $5.7M
- 13 awards
- Sector median: 1
- Raised
- $4.9M
- 3 Form D · Jul 2021
- 63 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 6
- 0 granted · 6 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20172019202120232025
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $6,000,000 | |
| Private capital raised | Form D · SEC | $3,402,923 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Optimization of microparticle-based topical treatments for treating erectile dysfunction in patients refractory to oral PDE5 inhibitors | $225,000 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Optimization of microparticle-based topical treatments for treating erectile dysfunction in patients refractory to oral PDE5 inhibitors | $225,000 | |
| Private capital raised | Form D · SEC | $1,543,194 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Development of microparticle-based topical treatments for treating erectile dysfunction in patients refractory to oral PDE5 inhibitors | $1,705,226 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Development of microparticle-based topical treatments for treating erectile dysfunction in patients refractory to oral PDE5 inhibitors | $697,168 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of microparticle-based topical treatments for treating erectile dysfunction in patients refractory to oral PDE5 inhibitors | $1,008,058 | |
| Federal grant | Department of Health and Human Services · Phase I · Development and optimization of a nitric oxide releasing microparticle-basedtopical treatment for onychomycosis | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Optimization of a nanoparticle-based topical PDE5i formulation for treatment of erectile dysfunction | $263,446 | |
| Federal grant | Department of Health and Human Services · Phase I · Optimization of a nanoparticle-based topical PDE5i formulation for treatment of erectile dysfunction | $263,446 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of an endocannabinoid microparticle formulation for the topical treatment of cutaneous manifestations of lupus erythematosus. | $147,861 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of an endocannabinoid microparticle formulation for the topical treatment of cutaneous manifestations of lupus erythematosus. | $147,861 | |
| Federal grant | Department of Health and Human Services · Phase I · Development and optimization of a nitric oxide releasing microparticle-basedtopical treatment for onychomycosis | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of an endocannabinoid microparticle formulation for the topical treatment of cutaneous manifestations of lupus erythematosus. | $145,888 | |
| Federal grant | Department of Health and Human Services · Phase I · Development and optimization of a nitric oxide releasing microparticle formulation for the topical treatment of chronic rhinosinusitis | $300,000 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2786 | CELL REPROGRAMMING & THERAPEUTICS LLC | — | — |
| 2787 | Veradermics | — | $269M |
| 2788 | Avalyn Pharma | — | $242M |
| 2789 | Zylo Therapeutics Inc. | — | $4.9M |
| 2790 | Arbor Biotechnologies | — | $227M |
| 2791 | Metsera | — | $215M |
| 2792 | Affinivax, Inc. | — | $233M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Gary AtkinsonDirector
- GARY ATKINSONDirector
- James CordesDirector
- Matt DunbarDirector
- Charles HinkleExecutive Officer
- Thomas MurrayExecutive Officer
- Scott PancoastDirector · Executive Officer · Promoter
- SCOTT PANCOASTDirector · Executive Officer
- MICHAEL RABINExecutive Officer
- Lance WhiteDirector
- LANCE WHITEDirector
Patents
- Sulfur Functionalized Monoliths And Particles Derived From The Same As Nitric Oxide Carriers For Pharmaceutical And Cosmetic Applicationsapplication
- Systems and Methods for Delivery of Nitric Oxideapplication
- Delivery Systems And Method Using Cannabinoids For Treatment Of Inflammatory Disordersapplication
- Sulfur Functionalized Monoliths And Particles Derived From The Same As Nitric Oxide Carriers For Pharmaceutical And Cosmetic Applicationsapplication
- Delivery Systems and Method Using Cannabinoids for Treatment of Inflammatory Diseasesapplication
- Sulfur Functionalized Monoliths and Particles Derived from the Same as Nitric Oxide Carriers for Pharmaceutical and Cosmetic Applicationsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.